# TLX007 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/tlx007

> The FDA approved TLX007, sponsored by Telix Pharmaceuticals Ltd (TLX), on March 20, 2025.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | TLX007 |
| Codes | TLX007 |
| Sponsor | Telix Pharmaceuticals Ltd (TLX) https://sec-api.dev/companies/tlx/catalysts |
| Indications |  |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Jul 2024: PDUFA date

- Status: scheduled. Date confidence: month.
- First seen 2025-02-24, last confirmed 2025-02-24.
- SEC Form 10-K (accession 0001140361-25-005562): "We have also submitted a new drug application, or NDA, to the FDA for TLX007-CDx for the imaging of prostate cancer, which was accepted by the FDA in July 2024 and assigned a Prescription Drug User Fee Action, or PDUFA, goal date of March 24," https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm

### March 20, 2025: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-03-21, last confirmed 2025-03-21.
- Press release filed with the SEC (EX-99) (accession 0002007191-25-000037): "Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging1 agent for prostate cancer." https://www.sec.gov/Archives/edgar/data/2007191/000200719125000037/gozpr.htm

### March 24, 2025: PDUFA date

- Status: completed, approved. Date confidence: exact.
- First seen 2025-02-24, last confirmed 2025-02-24.
- SEC Form 10-K (accession 0001140361-25-005562): "In July 2024, the FDA accepted the NDA for TLX007-CDx and assigned a PDUFA goal date of March 24, 2025." https://www.sec.gov/Archives/edgar/data/2007191/000114036125005562/ef20038762_20f.htm
- Press release filed with the SEC (EX-99) (accession 0002007191-25-000037): "Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Gozellix® (TLX007-CDx, kit for the preparation of gallium-68 (68Ga) gozetotide injection), Telix's next-generation PSMA-PET imaging1 agent for prostate cancer." https://www.sec.gov/Archives/edgar/data/2007191/000200719125000037/gozpr.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/tlx007.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "TLX007 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/tlx007

```bibtex
@misc{secapidev_pdufa_tlx007_20261116,
  title        = {TLX007 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/tlx007}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_tlx007_20261116","title":"TLX007 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/tlx007","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
